LSK doubles down on early oncology pipeline with Huntsman deal
By Marie Powers
Friday, August 7, 2015
LSK Biopharma inked an exclusive license agreement with the University of Utah's Huntsman Cancer Institute (HCI) to develop and commercialize HCI-1401, an orally bioavailable, small-molecule, irreversible inhibitor of Bruton's tyrosine kinase (BTK). The new asset doubles the cancer pipeline for the Salt Lake City-based biotech, which earlier this year completed a phase I/II trial of its lead compound, apatinib mesylate (YN968D1), in solid tumors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.